CADL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Candel Therapeutics Inc (CADL) is not a strong buy for a beginner, long-term investor at this time. The stock shows a bearish technical trend, no significant positive trading signals, and lacks compelling financial performance or immediate catalysts. While analysts maintain a Buy rating with an optimistic price target, the company's financials and lack of recent news or influential trading activity do not support an immediate investment decision.
The stock exhibits bearish technical indicators with SMA_200 > SMA_20 > SMA_5. The RSI is neutral at 44.026, and the MACD histogram is slightly positive at 0.0175 but contracting. Key support levels are at 4.697 and 4.551, while resistance levels are at 5.171 and 5.317. Overall, the trend suggests weakness.
Additionally, the company is progressing with its lung cancer trial and prostate launch plans.
The stock has shown a consistent downward price trend (-2.20% regular market change, -1.20% pre-market change). Financial performance remains weak with no revenue growth and significant net losses. No recent news, insider trading, or congress trading data to act as a catalyst.
In Q4 2025, revenue remained at $0 with no growth. Net income improved YoY but remains negative at -$29.5M. EPS improved to -0.54, up 35% YoY, but still negative. Gross margin remains at 0%. Overall, the financials are weak and do not support a strong buy case.
Analysts maintain a Buy rating with a price target increase from $22 to $26, citing positive Phase 2a data for aglatimagene in lung cancer. However, a recent target cut from $24 to $22 was attributed to dilution concerns. Analyst sentiment is cautiously optimistic.
